-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RdaTVQk16KrXI8CluerEoDgIhqAZGpTou1rMNYGa/L7y2TvXJv5ZCftb+f7cI3FG gN60Wn9VZXCIZrMVnC5IAw== 0000950144-08-000438.txt : 20080128 0000950144-08-000438.hdr.sgml : 20080128 20080128151705 ACCESSION NUMBER: 0000950144-08-000438 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20080128 ITEM INFORMATION: Changes in Registrant.s Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080128 DATE AS OF CHANGE: 20080128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROXYMED INC /FT LAUDERDALE/ CENTRAL INDEX KEY: 0000906337 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 650202059 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22052 FILM NUMBER: 08553827 BUSINESS ADDRESS: STREET 1: 1854 SHACKLEFORD COURT STREET 2: SUITE 200 CITY: NORCROSS STATE: GA ZIP: 30093 BUSINESS PHONE: 7708069918 MAIL ADDRESS: STREET 1: 1854 SHACKLEFORD COURT STREET 2: SUITE 200 CITY: NORCROSS STATE: GA ZIP: 30093 FORMER COMPANY: FORMER CONFORMED NAME: HMO PHARMACY INC DATE OF NAME CHANGE: 19930601 8-K 1 g11472e8vk.htm PROXYMED, INC. PROXYMED, INC.
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 28, 2008
PROXYMED, INC.
(Exact name of registrant as specified in its charter)
         
Florida   000-22052   65-0202059
(State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification No.)
1854 Shackleford Court, Suite 200,
Norcross, Georgia 30093-2924

(Address of principal executive offices)
(770) 806-9918
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 4.01     Changes in Registrant’s Certifying Accountant
     On January 28, 2008, the Company engaged UHY, LLP (“UHY”) as its new independent registered public accounting firm for the fiscal year ended December 31, 2007, which engagement shall be effective immediately. The decision to engage UHY was approved by the Company’s Audit Committee.
     In deciding to engage UHY, the Company’s Audit Committee reviewed auditor independence issues and existing commercial relationships with UHY and concluded that UHY has no commercial relationship with the Company that would impair UHY’s independence. During the years ended December 31, 2007 and 2006, neither the Company nor anyone acting on its behalf has consulted with UHY on any of the matters or events set forth in Item 304(a)(2) of Regulation S-K.
     The Company previously announced the resignation of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm in an 8-K filed on December 26, 2007.
Item 9.01     Financial Statements and Exhibit.
            (d)     Exhibits
         
Exhibit No.   Description
  99.1    
Press Release dated January 28, 2008.

 


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ProxyMed, Inc.
 
 
 
Date: January 28, 2008  /s/ John G. Lettko    
  John G. Lettko   
  President and Chief Executive Officer   
 

 

EX-99.1 2 g11472exv99w1.htm EX-99.1 PRESS RELEASE DATED JANUARY 24, 2008 EX-99.1 PRESS RELEASE DATED JANUARY 24, 2007
 

Exhibit 99.1
(MEDAVANT LOGO)
     
Investor Relations Contact:
  Media Contacts:
John G. Nesbett
  Teresa Stubbs
Institutional Marketing Services, Inc.
  MedAvant Healthcare Solutions
203-972-9200
  812-206-4332
jnesbett@institutionalms.com
  tstubbs@medavanthealth.com
MEDAVANT ANNOUNCES SELECTION OF NEW AUDITING FIRM
ATLANTA, GA.—(PRIME NEWSWIRE)—January 28, 2008-- MedAvant Healthcare Solutions (MedAvant) (NASDAQ: PILL), a leader in healthcare technology and transaction services, today announced it has engaged UHY LLP (UHY) as its independent public accounting firm effective immediately.
John Lettko, President and Chief Executive Officer of MedAvant, said, “After an extensive search, we are pleased to announce our engagement with UHY. We chose UHY because of their reputation for value-added service to their clients, their 30 years of experience, their expertise in our industry, and their focus on companies our size.”
MedAvant’s former auditing firm, Deloitte & Touche, resigned as auditors on December 26, 2007. The termination of that relationship was not the result of any disagreement between MedAvant and Deloitte &Touche on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure.
About MedAvant Healthcare Solutions
MedAvant provides information technology used to process transactions within the healthcare industry. MedAvant offers electronic claims processing to healthcare providers, a Preferred Provider Organization called the National Preferred Provider Network (NPPNTM) and remote reporting solutions for medical laboratories. To facilitate these services, MedAvant operates PhoenixSM, a highly scalable platform which supports real-time connections between healthcare clients. For more information, visit http://www.medavanthealth.com. MedAvant is a trade name of ProxyMed, Inc.
Forward Looking Statement
Statements in this release that are “forward-looking statements” are based on current expectations and assumptions that are subject to risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. Actual

 


 

results could differ materially from projected results because of factors such as: the soundness of our business strategies relative to the perceived market opportunities; MedAvant’s ability to successfully develop, market, sell, cross-sell, install and upgrade its clinical and financial transaction services and applications to current and new physicians, payers, medical laboratories and pharmacies; the ability to compete effectively on price and support services; MedAvant’s ability and that of its business associates to perform satisfactorily under the terms of its contractual obligations, and to comply with various government rules regarding healthcare and patient privacy; entry into markets with vigorous competition, market acceptance of existing products and services, changes in licensing programs, product price discounts, delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels; the availability of competitive products or services; the continued ability to protect the company’s intellectual property rights, implementation of operating cost structures that align with revenue growth; uninsured losses; adverse results in legal disputes resulting in liabilities; unanticipated tax liabilities; the effects of a natural disaster or other catastrophic event beyond our control that results in the destruction or disruption of any of our critical business or information technology systems. Any of these factors could cause the actual results to differ materially from the guidance given at this time. For further cautions about the risks of investing in MedAvant, we refer you to the documents MedAvant files from time to time with the Securities and Exchange Commission, including, without limitation, its most recently filed Annual Report on Form 10-K. MedAvant does not assume, and expressly disclaims, any obligation to update information contained in this document. Although this release may remain available on our website or elsewhere, its continued availability does not indicate that we are reaffirming or confirming any of the information contained herein.
###

 

GRAPHIC 3 g11472g1147201.gif GRAPHIC begin 644 g11472g1147201.gif M1TE&.#EA,`%?`(<```!(8P!)901+9@5,9@!+:`!,:`!.;`9-:`A.9PA.:`!0 M;@I0:@Q1:@Y2;`]4;0!1=B%@=R)@>"1B>2=D>B=D?"AD>REF?"QG?BMH?2QH?BYI@#!J@#)L M@31M@C9NA#EQACQSB#YTB4!VBD)WC$)XBT-XC$5ZC4=\CTA\CTI]D$Q^D4Z` MDE&"E%.$EE2$EE:&F%B'F5F(F5R*FUV*G%Z,G6&.GF./H&2/H&.0H&60H6B3 MHVF3I&F4HVJ4I&V6I6^8IW"8IW&9J'2;JG6=K'B>K'J@KGRAKGZBL$S' MZ$S(Z4W*[$[,[D[.\$_0\E')Z5#+[%7*Z53,ZU3,[%G*ZEG,ZEG,[%W-ZU#0 M\U#2]%'4]E'5^53;_U3<_V'.ZV7/[&?0[&K0[&[1['+2[';4[GC5[GS6[X&D MLH2FLX2GM(:HM8FJMHJKN(NLN(VMN9"ONY"OO)"PNY&PO)*PO).RO92RO9:T MOYBUOY>TP)BUP)BVP)JVP9NWPINXPIRXPIZYPYZZQ*"ZQ:&\Q:&\QJ*\Q:*\ MQJ2]QZ6^R('7[X#8[X;8[H+8\(G:\(S;\([<\9+<\)3=\9G>\9O@\J?`R:G! MRJK"S*S#S*W$S;#&SK''T++(T+3)T;?,T[C,T[C,U+K-U+K.U+O.UKS/UKW0 MU[[1V*#A\Z7C\J?C]*SE]++G];3G];+H];7H];GI]KWJ]L'2V3K M[N3L[N;M\.CN\>GO\N'U^N/W_.7V^^7W_.;X_.GP\NKP\NSQ\^WR]._T]>CX M_>WY_/#T]?#T]O+U]_+V]_/V^/3W^/'Z_?;X^?3[_?;\_?CZ^OG[_/K\_/S\ M_?S]_OW^_?S^_O[^_@```"'Y!````/\`+``````P`5\```C_`/T)'$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<)S MKA8!8L0+WD-PJPX!DN3+GDJB`8`!`H0$"#"3KJ%TIIL0*I4P(//J'7F/2H.Q M9@,+)E`!UD%#!P@(7BQ6@Z*]D"-+CAA-!H&XBQ<3L-"LH*D#F#,')CODZ>33 MJ"?S\@!8-&,%+'P*G";!0&C7<@NXD):ZMV^NI2@HQBVX`(G8"'8=C3JP=IB@%WT0$$`"I(3M,X M@OB2D"=NOO/Z_P!2U`L%[V5&EAX%L?/&&6^L4Y`0^^%60`G;!&CAA0HULT&$ MKA$`14'SQ%%&%5K`,4\_`\DS7G2!$>"":1C&>*$W*'`H&@$_\$.0/7)H4<6/ M9HH45/_Y(!B7V$#2-"$=JAD23 M9%Z'#P\%1(G4"N?LB$D96&99A15:8-+E0,184"!C`@L5G"*"80G8'65$&0`%;`_'#21:+,MKH)@5](@"E MHRU`2J:P=O_5R*J=,H!*09Y<:2JC='92T!^!- MM_26),T'\,KU1$&T7(%NNKOZ2PM!]-B0+P$S4%GOPAZ=L\+!/^A#D"W^`IRN MO[80::2:!/2@(\,@8R2/P1S7(`]!N'"!A<4`^YN+EV!RW$3(-%/$S[L/%RC];C,47QA#$2@/Y#N"L MTF`C!$BPT7D*JD#(B$&UG%;XBT466L0==Q;G6E'JCUAXD0Q!JH;_&T`#K(0M M^$"@@%;KK0-5(T866:ZKA1F*=C%&&VZ\8?D;:X"QQ15EF)'%%8MF$<8R!`'K MMP7"#![V*Y-V*D`C!%FS^)Q8>-[%&YS4HDPX[-33S^_]V%,/.]@80TLF;6Q1 M1AE49S&&-01=JV8`($RC>M+%:)!O`'@0A(T:GY>1A1J8Z"(.I`_9@TTME(!1 M!AE7.)]-J$&D&24!+,!X_<+$#)04`BR@!$(8!##T=YIOP$(///B```H0S$HA#9O6F0)YQ$*` M`Y2@"(PH!@;7`_\/7_BA!QU89SOC,PEX^J8/9.%E`#;0@T`0XQY,@D0;?1"&MZ`Z$:YD"`$5,YT*,&8@1."X4&0T:,50=@!>.(QC%`H M`H='!0H_F`$.P4W#>ED-JUC'2M:RFE4]DOC#1ZA@R&-MHPFR.2M'=)``L&ZD M%WWB5AT,X`BY#$`Z=@A(TR3BP4JM!!X[`(6PHA&-+;!C6Y8][K7 MY48S2A%'@VSC%;LHAC2DL8UI2)<8PAA&>H5!C.FB0Z8>&05F`F"*A.0#&*_H M13.D,0UN2",:P7A%,."KD'0\EQG\W48T@.$*YAXD'SIX3$48$07A1J09K^`% M,Z9K7F"T`FK+$8(@7"'>;6#WQ"BVKG^'00I)[%,?DMB%1A42BM%DH$T6\<8% M>IN`ZD#%"#;H0`(6(($*4&`!"V"`DAG0@`A((`$$\`%"5N&#&#R9`16`0`*H MPDYJ`J`!'%`!#^:`BJYNA`>7D4X/$N*.*.1`_YT'P+*2*6`#*.3V(,,H0@P: ML(`(.&``*?"!*A*RB^E@-2(X,,`03@N10/"@!10X0`0B<``/[*"@`Q&$`10C M``%```)^AD`#BER!"DA`U`Z8]*0EL`#07`!&=Q"""18"K!8AR")W@(X`9LP0 M?3P#3`E-P0E*0.P.7&``W;PU0O!!B@0D-``K^($2F&"$(NC`!1X80`$48("Q M9"`(KX(J0(BAE%17"0EB(P M%B)/A4!:0F`H@A2!G609P`$&,``(2(`"`WBV!"3``(8+(#=*^8`ZEB.,1BJD ME(+QP$@GH@[>QB4`D/^`R!1ZVP%WX.,>]Z`'/-0AC5.$Y1,,84%O=P#O@<0C M&J`HPH;&DB8;M+4B@B#`!HK4VSXTI`EQ(4`1),(/G1/`"`SQAIX"<(.*Y&`N M3+"(#R[CRX+@PP01D((JB-%?ZW[C'.J`NEQR<`YT>,.ZU"C&*P1A@P"(P-X- MP=EH`E&10L3G*')QI4/\T%L/$)@@ZMA`?1>"@]X>=B'>V`-KRE(`!M!AE!#A MQPL*$`1_;$HN*V`T0K9!(+E4P!P1&8:R*I#NA1RBMPSPL42^+B[13H1I`:B# M0:01`5`HA`J*"<`/%-*$$YSL(?N@@7E@T%L2`-XA\CA!`6B06J1/2%CEPO6&\(-(W`*+4#89T2(X>Q0^*,8R@+``(K%$'R?1<(/40=H M<7D*L0\O$'6#-1&\)R['-1%T<"`&,0HXL!#2$P!KEA#%L`+RUQ#91P`M<`K% M)1>',!&?0!:HP`>]=8$.(0DL1WX$P0^PL'$+D7X!L'X.40CY)Q9`H'H-,0<% MD`%=!5B6UQ"^<'%($0,]IQ#WD`(!D``LI1#`X&R]M0$R&!%?]WX`H&P0L2D! MH(4"T0UVA1`5J(('D0Y[D(0*X0T;4@/X(`.]90+/]Q#YP`(%H`+\0$=RX0(6 MMA`L*'XN*!$T:(,.`0J*A!1^`A'W,`)1-A"!,(6P_[<0_.`"<7$`6>$0NX!L M--`03D``);`"O24)"D@`$F"$\2$($F$Z7N@08]@1SR!P4B8*)[<($5%3!-!7 MI%!]AZ80?1@`XW<1@2@1MQ<7"%"H$.VO,!?V@0);@`SN`.&U`63KA[V^P^QB[TH=OXX$=T@36>Q"@YQ#F_!`P71 M"+VU`-OR<=!A?PP1"6@A?`QA`P4@`P*1!+T5=E:8E0*Q!,/Q-]W%$(X@%ZG8 M$*O($2AIBO[@#A[06RH0CPBQ`\:!8]VP8P`@`(:Q@OP(E.I'$78PELO7$!T5 M`'U%$-Z@100P!_]V$)356UW'$-(G`;RQ$,V@+&ZY"Q<7`!I@9@_AC2ZP)/K@ M?W+1`$;9$&>9DA*QEAL!?#@G$*-V%A:?I#`O!#%!6>@PQ!Z((5O>@`KT%@`[A MC7/_*1#WD'YR00&O\)L0V)KHV!';E)K^T`U&4UI[>!!&L!G,Z0_XX(EHV9-_ M61'#J8`GEYY0(0$$@`./*5^!@3@+00HM0@<+(4\#<'X((0\D0``Y0!!@)!H!"?()$($:`2,39G,1^T1A:(4(8=B112QA#R@%)R40)T*1#N$`(% M$`/U:1"G(!?D*!#0H$@#8**A.2$;^"0DF@%G@Q`.RIH1X9H9<0\F$``,X&#) M:%MRH:4*\00%$`&7.1!$D'Q`X)]F40&1(`J@$`J@@*B)_Y`'-:!Q#$&D$<&9 MTL%:"J$/'!0!^C@0W3`" M),H!G)40V>BF$`&G&$&1`6`!0GH$8SFJ!;$-%E``26`0(!<`V^B7@6$`SMIM MSUH`!C"9,QB4%#$-$:!:_V@0P@!E-:`/^!"NXHH/^E`*I(BD"T$-V8H4@XH0 M(_H!US=\!MJN!+&+%K`SX5D`%FD0W;`"L\H,">$*JY*6#*&K%^$,V2H"[U`0 MQ)"##8D0@]EC!I$'O54"&ZB+<=$`1M`$1Q`$0:`#-H`""5``VWH0D@H1ZE`! MTA%#"C&2$G`")A"S,FL")_`!H__!`E5:$$`P'!1@IP/1#']QB`NA!XI1E@*! M#GH9`(27KQL`FEX"6=)!`@57$*\PL"II@1S1"Z#!`CS8`V/9EP6!#ARPB`;Q M"'%A`3C&$+OXHP9Q7QR0H]4:F!3Q#HSIE0A!#[RI?W8D%V8A`!2*$+!PK@=! M!7T:A@C1G03PDP6Q1*A'D`?AC1R0M@5Q+\-1`";PJ011M>_TINVY$2A*`#?P MF+]`*Z![$(!03V1:$#4E%Q!`G3W*BZ\Z$%,P!0UQL@_A#EH4``V($*U`%C;@ M#,\@7<(KO-(@"@=P%@1XJ3HG%SA;$'!9`"R[$(%+`,E+$*YPO'M)H`R1`P2@ M`?EI$,S_P$IF48>2]141YP=7RY(6T8@$(`0?.AP36A#T<*'46A#`8#CQ^[J* M6Q"@\*4*8;L.P0T3+@Y2Q``W!!1Z)$`BQ#G@`&]6KX)00@G]P@- M\0U$&0#5BY4R\)@&\0T68!;8FQF=UEL2@+D)P;T68+@&\0L54+DR8&_"T,)7 M^Z0:401H<0=G/!P)<#;WX*](R,3SB:Y"'``<$)P/<<0,H<-R_W$"%TL0.MPQ M#=$->!H`,^"A!,$$PZ$!(T<,H!'$"8$(9+$$SN`,S4#*IMP,T+`*ZXJK>1P! MKJL0NR`/(@P!3YD0L-#&:B93TZ`LN)RKR5<#^Z`1[@@`QDP0O!<`"X`>^C`# M=9BS^-`"JA7"@WP"15R[UBH1[MB$W&P0S@`!`7`!3JL0IV"$!$#-"U%!`BD0 MX*`!!:!X"A$,B4$#7$P0JG!R#)K'$/^@>])K-$@Q!!(3#?A\M3;0SQG1#CLV M`+N@$%HK':4'"Q&7F&?<6S9@R0.QBQ#=CW(K$37II`IA263+@2306_#:$!.L MS=61"(3QO0FQB;[,$/2``CLGPB_Z$*S36P00=MV@T?F\-,GWTQHA#1K=`#;] MN,.ASF@B`LY,$/6GMBGD-U!CA M"Q%7`3YK$$786RO```2PM,(C=V`OQ`\E7F+,(&@2`QPEQO[&E MW`HA>Y+I$'3_D'PG4((#@!X,48($X-`*P0WKVIC=2`#[-XL.,)9)8-L3T:EZ MG1'RM5"&/!#\=A:\V,`'L0>XI\8'46L!8`**/1#O``J.*Q`ZH%I*&1'0$)<% M@`,-3DII@=X,P0]N*!<%W1#1T#H"<`$$8`,.,1X!0*,,@3/,'*\#H9P"X`H2 M<0JM]WZWW1"=^JT:(<4'GN`$8<-GL;L*,0FC`9\*@0?_>1#$$`-%W'=R47+1&*$'5&\-(%X;7^/7G5Z1X@8,Z`:X0`$,X($18I/A&O M0,^!<>/]UULML*43(4_0YMQ@?MH,L0JD*+0*D5R>>N09FA#XL+R^_P75`Z$/ MA5`![#0#^)H0.CPLO\T0\LECKYT0,7T6X\D048`6W]<0W?F.A2V$*$<1\PP= MT0#=M;(M`.CAT84,"-K%`!H6X0I@W&@MS9 MH\!!!I``4`#K`I$.*!4`*&#G"^%^TL$"SDZ>WBD7G\00T@`N6=YH)P>A!X$/ M;)U7J&X!P['J"H'H&G!G$C$,DW)'(+;B?4K"*PT:O>4#FTHPO-E;I14%?4`( M!+\'46`#!U``EY(0ZXB%-V`(O"`-WZ`.%.\-Q``*3``"VP8`1I=U_P:7/A`G=0"K0NO_>9%.RD`!(`!'6@X@6A8P7@=`%;!T5@ M`;8A%BF`!Q'( M,`JG0/Z/H`=2@`0]0`,K<`(H@`(`L6+'E$_#[OE#F%`A0GR@\N11]*G4J5.B M!N4IM5#C0GRN2GT"^>@0'SQY4.W;B!#/"7NG4F
-----END PRIVACY-ENHANCED MESSAGE-----